Table 2.

Clinical implication of miR-1258 in human cancers.

Cancertype	Sources	Sample number	Aggressive phenotype of low miR-1258	Prognosis of low miR-1258	References
HCC	Tissues	20	Yes	Worse DFS	[24]
HCC	Tissues	20	/	Worse OS and RFS	[25]
GC	Tissues	116	Yes	/	[26]
CRC	Tissues	60	Yes	/	[28]
OSCC	Tissues	89	/	Worse OS and DFS	[30]
BC	Tissues	1062	Yes	Worse OS	[36]
BC	Tissues	105	Yes	Worse OS and RFS	[39]
Myeloma	Tissues	63	/	Worse PFS	[42]
Glioblastoma	Tissues	33	Yes	/	[44]
Osteosarcoma	Tissues	60	Yes	Worse OS	[45]

BC, breast cancer; HCC, hepatocellular carcinoma; GC, gastric cancer; OSCC, oral squamous cell carcinoma; CRC, colorectal cancer; PFS, progression-free survival; OS, overall survival; DFS, disease-free survival; RFS, relapse-free survival.